|
US5538983A
(en)
|
1990-05-16 |
1996-07-23 |
The Rockefeller University |
Method of treating amyloidosis by modulation of calcium
|
|
JPH06509576A
(ja)
|
1991-07-29 |
1994-10-27 |
ワーナー−ランバート・コンパニー |
アセチルコリンエステラーゼ阻害剤としてのキナゾリン誘導体
|
|
IT1255179B
(it)
|
1992-06-26 |
1995-10-20 |
Enzo Cereda |
Azaciclo e azabiciclo alchiliden idrossilamine
|
|
US5744476A
(en)
|
1994-06-27 |
1998-04-28 |
Interneuron Pharmaceuticals, Inc. |
Dopamine D1 agonists for the treatment of dementia
|
|
JP2992677B2
(ja)
|
1995-06-05 |
1999-12-20 |
武田薬品工業株式会社 |
骨形成促進医薬組成物
|
|
WO1998030243A1
(en)
|
1997-01-08 |
1998-07-16 |
Warner-Lambert Company |
Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease
|
|
JP2002509128A
(ja)
|
1998-01-16 |
2002-03-26 |
パーデュー・リサーチ・ファウンデーション |
アルケニルジアリールメタン非ヌクレオシドｈｉｖ−１逆転写酵素インヒビタ
|
|
WO1999037304A1
(en)
|
1998-01-27 |
1999-07-29 |
Aventis Pharmaceuticals Products Inc. |
SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS
|
|
JP2003529531A
(ja)
|
1998-11-25 |
2003-10-07 |
アヴェンティス ファーマシューティカルズ インコーポレイテッド |
置換オキソアザへテロシクリルＸａ因子阻害剤
|
|
WO2001007436A2
(en)
|
1999-07-28 |
2001-02-01 |
Aventis Pharmaceuticals Inc. |
Substituted oxoazaheterocyclyl compounds
|
|
JP2001131173A
(ja)
|
1999-08-23 |
2001-05-15 |
Kyorin Pharmaceut Co Ltd |
二環式複素環誘導体
|
|
JP2005231995A
(ja)
|
1999-12-22 |
2005-09-02 |
Meiji Seika Kaisha Ltd |
オピオイドδ受容体アゴニスト／アンタゴニストとして有用なスピロ化合物
|
|
US7084126B1
(en)
|
2000-05-01 |
2006-08-01 |
Healthpartners Research Foundation |
Methods and compositions for enhancing cellular function through protection of tissue components
|
|
JP2004502655A
(ja)
|
2000-06-30 |
2004-01-29 |
イーライ・リリー・アンド・カンパニー |
精神病の処置のための組み合わせ療法
|
|
CA2442717A1
(en)
|
2001-03-15 |
2002-09-26 |
Saegis Pharmaceuticals, Inc. |
Methods for restoring cognitive function following systemic stress
|
|
US20040023951A1
(en)
|
2001-06-18 |
2004-02-05 |
Bymaster Franklin Porter |
Combination therapy for treatment of psychoses
|
|
US20030004913A1
(en)
|
2001-07-02 |
2003-01-02 |
Koninklijke Philips Electronics N.V. |
Vision-based method and apparatus for detecting an event requiring assistance or documentation
|
|
CZ2004632A3
(cs)
|
2001-11-26 |
2004-08-18 |
Cortexápharmaceuticalsźáinc |
Karbonylbenzoxazinové sloučeniny pro zvýšení glutamátergních synaptických odpovědí
|
|
US20040044023A1
(en)
|
2002-08-30 |
2004-03-04 |
Marc Cantillon |
Compositions and methods for treating or preventing memory impairment
|
|
EP1596867A4
(en)
|
2003-02-19 |
2006-03-22 |
Merck & Co Inc |
TREATMENT OF PSYCHOSIS WITH A MUSCARIN M1 RECEPTOR ECTOPIC ACTIVATOR
|
|
AU2004226430A1
(en)
|
2003-03-28 |
2004-10-14 |
Acadia Pharmaceuticals Inc. |
Muscarinic M1 receptor agonists for pain management
|
|
US20040266659A1
(en)
|
2003-06-27 |
2004-12-30 |
Stephen LaBerge |
Substances that enhance recall and lucidity during dreaming
|
|
GB0504019D0
(en)
|
2005-02-26 |
2005-04-06 |
Astrazeneca Ab |
Amide derivatives
|
|
JP2008537887A
(ja)
|
2005-04-15 |
2008-10-02 |
ボード、オブ、トラスティーズ、オブ、ミシガン、ステイト、ユニバーシティ |
アスコルベート結合ペプチド
|
|
GB0516570D0
(en)
|
2005-08-12 |
2005-09-21 |
Astrazeneca Ab |
Amide derivatives
|
|
JP2009506069A
(ja)
|
2005-08-26 |
2009-02-12 |
ブレインセルス，インコーポレイティド |
ムスカリン性受容体調節による神経発生
|
|
US20110319386A1
(en)
|
2005-08-26 |
2011-12-29 |
Braincells Inc. |
Neurogenesis by muscarinic receptor modulation
|
|
WO2007044937A2
(en)
|
2005-10-13 |
2007-04-19 |
President And Fellows Of Harvard College |
Compositions and methods to modulate memory
|
|
PT1966214T
(pt)
|
2005-12-21 |
2017-02-03 |
Janssen Pharmaceutica Nv |
Triazolpiridazinas como moduladores de tirosina quinase
|
|
GB0607952D0
(en)
|
2006-04-21 |
2006-05-31 |
Minster Res Ltd |
Novel treatment
|
|
GB0607946D0
(en)
|
2006-04-21 |
2006-05-31 |
Minster Res The Ltd |
Mono and combination therapy
|
|
GB0607949D0
(en)
|
2006-04-21 |
2006-05-31 |
Minster Res The Ltd |
Mono and combination therapy
|
|
US8217177B2
(en)
|
2006-07-14 |
2012-07-10 |
Amgen Inc. |
Fused heterocyclic derivatives and methods of use
|
|
US8198448B2
(en)
|
2006-07-14 |
2012-06-12 |
Amgen Inc. |
Fused heterocyclic derivatives and methods of use
|
|
PE20080403A1
(es)
|
2006-07-14 |
2008-04-25 |
Amgen Inc |
Derivados heterociclicos fusionados y metodos de uso
|
|
US7834023B2
(en)
|
2006-09-20 |
2010-11-16 |
Portola Pharmaceuticals, Inc. |
Substituted dihydroquinazolines as platelet ADP receptor inhibitors
|
|
WO2008085506A1
(en)
*
|
2007-01-03 |
2008-07-17 |
Cortex Pharmaceuticals, Inc. |
3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses
|
|
WO2008113072A2
(en)
|
2007-03-15 |
2008-09-18 |
Board Of Regents, The University Of Texas System |
Gpcr enhanced neuroprotection to treat brain injury
|
|
RU2010111550A
(ru)
|
2007-08-29 |
2011-10-10 |
Шеринг Корпорейшн (US) |
2,3-замещенные индольные производные для лечения вирусных инфекций
|
|
JP5258889B2
(ja)
|
2007-08-29 |
2013-08-07 |
メルク・シャープ・アンド・ドーム・コーポレーション |
ウイルス感染症の治療のための２，３−置換アザインドール誘導体
|
|
CA2697454C
(en)
|
2007-08-29 |
2015-11-03 |
Schering Corporation |
2-carboxy substituted indole derivatives and methods of use thereof
|
|
CA2700332A1
(en)
|
2007-09-21 |
2009-03-26 |
Acadia Pharmaceuticals, Inc. |
N-substituted piperidine derivatives as serotonin receptor agents
|
|
SI2200610T1
(en)
|
2007-09-21 |
2018-06-29 |
Acadia Pharmaceuticals Inc. |
Co-administration of pimavanserin with other agents
|
|
EP2222672B1
(en)
|
2007-11-16 |
2013-12-18 |
Merck Sharp & Dohme Corp. |
3-aminosulfonyl substituted indole derivatives and methods of use thereof
|
|
MX2010005356A
(es)
|
2007-11-16 |
2010-05-27 |
Schering Corp |
Derivados de indol 3-heterociclico sustituidos y metodos de uso de los mismos.
|
|
US20110024198A1
(en)
|
2008-02-19 |
2011-02-03 |
Baker Hughes Incorporated |
Bearing systems containing diamond enhanced materials and downhole applications for same
|
|
WO2010042603A1
(en)
|
2008-10-08 |
2010-04-15 |
Cingulate Neuro Therapeutics, Llc |
Amyloid and depression
|
|
PE20120031A1
(es)
|
2008-11-20 |
2012-02-05 |
Merck Sharp & Dohme |
Compuestos aril metil benzoquinazolinona como moduladores alostericos positivos del receptor m1
|
|
JP2012518640A
(ja)
|
2009-02-23 |
2012-08-16 |
メルク・シャープ・エンド・ドーム・コーポレイション |
ピラゾロ［４，３−ｃ］シンノリン−３−オンＭ１受容体陽性アロステリックモジュレーター
|
|
US20120046273A1
(en)
|
2009-03-05 |
2012-02-23 |
Mithridion, Inc. |
Compounds and compositions for cognition-enhancement, methods of making, and methods of treating
|
|
WO2010123716A1
(en)
|
2009-04-20 |
2010-10-28 |
Merck Sharp & Dohme Corp. |
Heterocyclic fused cinnoline m1 receptor positive allosteric modulators
|
|
ES2353093B1
(es)
|
2009-05-20 |
2012-01-03 |
Consejo Superior De Investigaciones Científicas (Csic) |
Uso de derivados de quinazolinas y sus composiciones farmacéuticas en enfermedades neurodegenerativas.
|
|
US10265311B2
(en)
|
2009-07-22 |
2019-04-23 |
PureTech Health LLC |
Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
|
|
EP3061821B1
(en)
|
2009-07-22 |
2019-07-10 |
Puretech Health LLC |
Compositions for treatment of disorders ameliorated by muscarinic receptor activation
|
|
MY160075A
(en)
|
2009-08-31 |
2017-02-15 |
Merck Sharp & Dohme |
Pyranyl aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
|
|
WO2011049731A1
(en)
|
2009-10-21 |
2011-04-28 |
Merck Sharp & Dohme Corp. |
Quinolinone-pyrazolone m1 receptor positive allosteric modulators
|
|
EP2512245B1
(en)
|
2009-12-14 |
2014-07-23 |
Merck Sharp & Dohme Corp. |
Pyridoquinazolinone m1 receptor positive allosteric modulators
|
|
US8383638B2
(en)
|
2009-12-21 |
2013-02-26 |
Merck Sharp & Dohme |
Aminobenzoquinazolinone M1 receptor positive allosteric modulators
|
|
WO2011159553A1
(en)
*
|
2010-06-15 |
2011-12-22 |
Merck Sharp & Dohme Corp. |
Heterocyclic fused phenanthrolinone m1 receptor positive allosteric modulators
|
|
WO2012003147A1
(en)
|
2010-07-01 |
2012-01-05 |
Merck Sharp & Dohme Corp. |
Isoindolone m1 receptor positive allosteric modulators
|
|
US8664234B2
(en)
|
2010-10-04 |
2014-03-04 |
Merck Sharp & Dohme Corp. |
Dihydrobenzoquinazolinone M1 receptor positive allosteric modulators
|
|
WO2012149524A1
(en)
|
2011-04-29 |
2012-11-01 |
The University Of Toledo |
Muscarinic agonists as enhancers of working memory and cognitive flexibility
|
|
WO2012158473A1
(en)
*
|
2011-05-17 |
2012-11-22 |
Merck Sharp & Dohme Corp. |
N-methyl tetrahydroquinoline m1 receptor positive allosteric modulators
|
|
WO2012170599A1
(en)
|
2011-06-10 |
2012-12-13 |
Braincells, Inc. |
Neurogenesis by muscarinic receptor modulation
|
|
EP2821401B1
(en)
|
2012-03-02 |
2020-09-09 |
Takeda Pharmaceutical Company Limited |
Dihydroquinolinone compounds as modulators of the muscarininc m1 receptor
|
|
CA2868026C
(en)
|
2012-03-23 |
2021-02-16 |
Ptc Therapeutics, Inc. |
Compounds for treating spinal muscular atrophy
|
|
US20130289019A1
(en)
|
2012-04-26 |
2013-10-31 |
Amazing Grace, Inc. |
Methods of treating behaviorial and/or mental disorders
|
|
EP2921480B1
(en)
|
2012-11-19 |
2017-10-11 |
Takeda Pharmaceutical Company Limited |
Nitrogen-containing heterocyclic compound
|
|
JP6075408B2
(ja)
|
2012-11-22 |
2017-02-08 |
株式会社デンソー |
物標検出装置
|
|
MX2015006437A
(es)
|
2012-12-27 |
2015-08-14 |
Hoffmann La Roche |
Inhibidores de la enzima catecol-o-metiltransferasa (comt).
|
|
JP6402115B2
(ja)
|
2013-02-04 |
2018-10-10 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ |
神経学的疾患および状態の処置に有用なスピロ−キナゾリノン誘導体
|
|
US10738024B2
(en)
|
2013-05-06 |
2020-08-11 |
Indiana University Research And Technology Corporation |
Compounds for treatment of angiogenesis-mediated diseases
|
|
JP6063400B2
(ja)
|
2014-01-08 |
2017-01-18 |
株式会社日立ビルシステム |
エレベータの異常監視装置
|
|
MX373274B
(es)
|
2014-04-23 |
2020-04-16 |
Takeda Pharmaceuticals Co |
Derivados de isoindolin-1-ona con actividad de modulador alostérico positivo del receptor colinérgico muscarínico m1 para el tratamiento de la enfermedad de alzheimer.
|
|
JP6531093B2
(ja)
|
2014-05-16 |
2019-06-12 |
武田薬品工業株式会社 |
含窒素複素環化合物
|
|
WO2015190564A1
(ja)
|
2014-06-13 |
2015-12-17 |
武田薬品工業株式会社 |
含窒素複素環化合物
|
|
KR20180019234A
(ko)
*
|
2015-06-26 |
2018-02-23 |
다케다 야쿠힌 고교 가부시키가이샤 |
콜린성 무스카린 m1 수용체의 조절제로서의 2,3-디히드로-4h-1,3-벤족사진-4-온 유도체
|
|
US20180250270A1
(en)
|
2015-09-11 |
2018-09-06 |
Chase Pharmaceuticals Corporation |
Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system
|
|
WO2017069173A1
(ja)
|
2015-10-20 |
2017-04-27 |
武田薬品工業株式会社 |
複素環化合物
|
|
EP3428150B1
(en)
|
2016-03-11 |
2023-07-12 |
Takeda Pharmaceutical Company Limited |
Aromatic ring compound having a cholinergic muscarine m1 receptor positive allosteric modulator activity
|
|
EP3562477A4
(en)
|
2016-12-29 |
2020-11-18 |
Synnerva Ltd. |
PROCEDURES AND COMPOSITIONS FOR POTENTIATING CNS DRUGS AND REDUCING THEIR SIDE EFFECTS
|